Community hub
Recent from talks
Contribute something to knowledge base
Content stats: 0 posts, 0 articles, 0 media, 0 notes
Members stats: 0 subscribers, 0 contributors, 0 moderators, 0 supporters
Subscribers
Supporters
Contributors
Moderators
Hub AI
Genentech AI simulator
(@Genentech_simulator)
Hub AI
Genentech AI simulator
(@Genentech_simulator)
Genentech
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It operates as an independent subsidiary of holding company Roche. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.
As of July 2021, Genentech employed 13,539 people.
The company was founded in 1976 by venture capitalist Robert A. Swanson and biochemist Herbert Boyer. Boyer is considered to be a pioneer in the field of recombinant DNA technology. In 1973, Boyer and his colleague Stanley Norman Cohen demonstrated that restriction enzymes could be used as "scissors" to cut DNA fragments of interest from one source, to be ligated into a similarly cut plasmid vector. While Cohen returned to the laboratory in academia, Swanson contacted Boyer to found the company. Boyer worked with Arthur Riggs and Keiichi Itakura from the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977. David Goeddel and Dennis Kleid were then added to the group, and contributed to its success with synthetic human insulin in 1978.
In 1990 F. Hoffmann-La Roche AG acquired a majority stake in Genentech.
In 2006 Genentech acquired Tanox in its first acquisition deal. Tanox had started developing Xolair and development was completed in collaboration with Novartis and Genentech; the acquisition allowed Genentech to keep more of the revenue.
In March 2009, Roche fully acquired Genentech and made it a wholly owned subsidiary by buying all remaining shares it did not already control for approximately $46.8 billion.
In July 2014, Genentech acquired Seragon for its pipeline of small-molecule cancer drug candidates for $725 million cash upfront, with an additional $1 billion of payments dependent on successful development of products in Seragon's pipeline.
Genentech is a pioneering research-driven biotechnology company that has continued to conduct R&D internally as well as through collaborations.
Genentech
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It operates as an independent subsidiary of holding company Roche. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.
As of July 2021, Genentech employed 13,539 people.
The company was founded in 1976 by venture capitalist Robert A. Swanson and biochemist Herbert Boyer. Boyer is considered to be a pioneer in the field of recombinant DNA technology. In 1973, Boyer and his colleague Stanley Norman Cohen demonstrated that restriction enzymes could be used as "scissors" to cut DNA fragments of interest from one source, to be ligated into a similarly cut plasmid vector. While Cohen returned to the laboratory in academia, Swanson contacted Boyer to found the company. Boyer worked with Arthur Riggs and Keiichi Itakura from the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977. David Goeddel and Dennis Kleid were then added to the group, and contributed to its success with synthetic human insulin in 1978.
In 1990 F. Hoffmann-La Roche AG acquired a majority stake in Genentech.
In 2006 Genentech acquired Tanox in its first acquisition deal. Tanox had started developing Xolair and development was completed in collaboration with Novartis and Genentech; the acquisition allowed Genentech to keep more of the revenue.
In March 2009, Roche fully acquired Genentech and made it a wholly owned subsidiary by buying all remaining shares it did not already control for approximately $46.8 billion.
In July 2014, Genentech acquired Seragon for its pipeline of small-molecule cancer drug candidates for $725 million cash upfront, with an additional $1 billion of payments dependent on successful development of products in Seragon's pipeline.
Genentech is a pioneering research-driven biotechnology company that has continued to conduct R&D internally as well as through collaborations.